Latest news - Novo Nordisk
WEBAug 6, 2024 · Latest news. 20 September 2024. Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed. Read more. 19 September 2024. Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function. Read more. 06 …
Novo Nordisk Just Committed More Than $1.1 Billion to Make …
WEB3 days ago · In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim ...
Novo Nordisk to boost output of Wegovy, Ozempic with new NC …
WEBJun 24, 2024 · Novo Nordisk on Monday said it will spend $4.1 billion to build a new manufacturing plant in Clayton, North Carolina, in a bid to boost the supply of its blockbuster weight loss drug Wegovy ...
Inside Novo Nordisk, the Company Behind Ozempic and Wegovy …
WEBApr 20, 2024 · Novo Nordisk’s factories work nonstop turning out Ozempic and Wegovy, its blockbuster weight-loss drugs, but the Danish company has far bigger ambitions.
Novo Nordisk signs deals worth up to $1bn with US biotechs in …
WEBJan 4, 2024 · Novo Nordisk has signed deals worth up to $1bn with US biotech start-ups developing treatments for obesity and other cardiometabolic diseases, as the Wegovy manufacturer seeks to stay ahead in...
Novo Nordisk expects double-digit growth as it boosts Wegovy …
WEBCOPENHAGEN/LONDON, Jan 31 (Reuters) - Novo Nordisk on Wednesday forecast another year of double-digit growth as the Danish drugmaker began boosting U.S. supplies of its popular weight-loss drug...
News Details - Novo Nordisk
WEBMar 5, 2024 · Novo Nordisk A/S: Semaglutide 1.0 mg demonstrates 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease in the FLOW trial. Bagsværd, Denmark, 5 March 2024 – Novo Nordisk today announced the headline results from the kidney outcomes trial FLOW.
Novo Nordisk Wegovy approved for cutting heart disease risks
WEBMar 8, 2024 · The Food and Drug Administration approved Novo Nordisk’s blockbuster weight loss drug Wegovy for use in slashing the risk of serious cardiovascular complications in people with obesity and heart ...
Novo Nordisk's Ozempic cuts risk of kidney disease progression
WEBMar 5, 2024 · Novo Nordisk ’s blockbuster drug Ozempic cut the risk of kidney disease progression and related health complications in diabetic patients, according to initial late-stage trial results released ...
News Details - Novo Nordisk
WEBMar 28, 2022 · Novo Nordisk expects to launch Ozempic ® 2.0 mg in the United States in the second quarter of 2022. Ozempic ® 2.0 mg is now approved in the US, the EU, Canada and Switzerland. About the SUSTAIN clinical programme.
- Some results have been removed